Goldman Sachs Maintains Buy on Abbott Laboratories, Lowers Price Target to $121

Benzinga Newsdesk www.benzinga.com Neutral 45.3%

Neg 0% Neu 45.3% Pos 0%

Goldman Sachs analyst David Roman maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $140 to $121.